Seven years of outstanding safety profile in AZ, PDD and Rett. Also current drug trial result prove better than the current SOC. A2-73 should be approved now with it's track record and the highly unmet need in the CNS space.
Many people are needlessly dying early not having access to this drug. Also, preventing them from a better quality of life in general. imo
The 130 genetic before and after sequences are also PD samples.
Pretty sure the same hunt for PD motor gene clusters has been or is being done to generate a PD biomarker hypothesis to first test and perhaps establish in a P2 trial before going for a proper Precision Medicine P3 trial.
Still lots of time to rename the trial too e.g. as a P2/3.
Perhaps Missling feels measure twice and run one correct trial to rule them all is worthwhile to exclude all competition for a while and with at least one other biomarker patent filed just like the recent one, but claims being with regards to motor gene clusters.
News 
Market Data 
Discover 
